TBPN Peptide Debate Recap, John Ternus Rumors Swirl, OpenAI Nonprofit to Spend $1B | Diet TBPN
35 snips
Mar 24, 2026 A rapid tour through the peptide fight, framed around risk, anecdotes, and gray-market tension. Then the spotlight shifts to rumors about Apple’s next leader and the management drama around a Vision Pro and AirPods mix-up. It also hits OpenAI’s reported $1B nonprofit spending, Meta’s AI reshuffle, and the geopolitics of EV batteries.
AI Snips
Chapters
Transcript
Episode notes
Why The Peptide Debate Stayed Unresolved
- John Coogan framed the peptide fight as a real split between unknown risks and strong anecdotal results, not a debate likely to end with consensus.
- He argued live fact-checking should mostly come from the debaters and chat because heavy moderator intervention would disrupt the format.
Two Competing Theories Of The Peptide Market
- The peptide argument turned on whether gray-market experimentation is irrational fad behavior or a harm-reduction opportunity that should be legalized and regulated.
- John Coogan contrasted Martin Shkreli's shut-it-down stance with Max's claim that some peptides likely work and a white market would be safer.
Why John Ternus Looks Like Apple's Heir
- John Ternus looks like Apple's leading internal successor because Tim Cook is preparing for generational turnover while keeping succession in-house.
- Mark Gurman's profile says Ternus now fronts launches, oversees hardware driving roughly 80% of revenue, and is young enough for a long run.